DBV Technologies: Last patient visit in the SPEED trial

DBV Technologies announced the completion of patient visits for its Phase 3 VITESSE study of the VIASKIN® Peanut patch. This treatment targets children aged 4 to 7 years with peanut allergies. With patient visits now complete, the company is on track to publish study results by the end of the year.

Daniel Tassé, CEO, emphasized the importance of this milestone in providing a new therapeutic option, subject to approval. This study, involving 654 children, is the largest in the field of peanut allergy, conducted at various global sites. DBV Technologies continues to advance in the treatment of food allergies.